New-Delhi metallo-β-lactamase-1 (NDM-1) is one of the most concerning antibiotic resistance mechanisms discovered in the last two decades. It represents a major public health challenge due to its ability to make bacteria resistant to a wide range of antibiotics, especially carbapenems, our “last-line” drugs for severe infections. This blog will explore what NDM-1 is, how it works, its global spread and implications, detection and prevention, treatment limitations, and what the future holds.
NDM-1 (New-Delhi metallo-β-lactamase-1) is an enzyme produced by certain bacteria that makes them resistant to many of the most powerful antibiotics available, especially beta-lactam antibiotics including carbapenems. Carbapenems are often considered drugs of last resort when treating multidrug-resistant infections. The enzyme breaks down these antibiotics before they can kill the bacteria, rendering treatment ineffective.
NDM-1 is not a bacteria itself, it is a resistance gene (bla_NDM-1) carried by bacteria such as Klebsiella pneumoniae and Escherichia coli. Bacteria carrying this gene are often called “superbugs” due to their high resistance.
What makes NDM-1 particularly dangerous is that the gene is often located on plasmids, small, transferable pieces of DNA that bacteria can easily pass to one another through horizontal gene transfer. This allows the resistance to spread rapidly between different species of bacteria. (SpringerLink)
NDM-1 was first identified in 2008 in a Klebsiella pneumoniae sample from a Swedish patient who had been hospitalized in New Delhi, India. Researchers named the resistance gene after the city where the patient received care.
Although initial reports linked the emergence of NDM-1 to South Asia, subsequent studies found that the gene was circulating in clinical and environmental settings in many other countries just years later. Isolates have been reported across Europe, North America, Asia, Africa and other regions, illustrating its rapid global spread.
The exact geographical origin of the gene remains uncertain, as it may have existed undetected in environmental reservoirs or bacterial populations before its discovery. Regardless, what is clear is that NDM-1 has become endemic in parts of South Asia and widespread internationally.
The NDM-1 enzyme belongs to a class of enzymes called metallo-β-lactamases, specifically class B carbapenemases. These enzymes have two zinc ions in their active site, which they use to break open the beta-lactam ring structure shared by many antibiotics. Once this ring is broken, the antibiotic loses its ability to interfere with bacterial cell wall synthesis, allowing the bacteria to survive and multiply despite treatment.
This mechanism enables NDM-1 producing bacteria to inactivate:
However, because NDM-1 specifically targets beta-lactams, some non-beta-lactam antibiotics retain activity, but in many isolates, additional resistance mechanisms make even these options ineffective.
Carbapenems were developed to treat infections caused by multidrug-resistant bacteria. NDM-1 deactivates these antibiotics, leaving clinicians with very few effective options.
A Public Health England study found that NDM-1-positive bacteria were resistant to nearly all tested carbapenems, and only a small fraction were susceptible to other antibiotic classes. Tigecycline and colistin, antibiotics with notable side effects, sometimes remain effective but are not ideal for all infections. (GOV.UK)
Because the nitrogen-encoded gene is plasmid-borne, it can rapidly transfer among bacteria, even between different genera. This accelerates the spread of resistance within clinical and community settings. (SpringerLink)
Some bacteria carry NDM-1 without expressing it at high levels, making routine tests unable to detect them. These silent carriers can survive antibiotic exposure and later become fully resistant via genetic activation. This phenomenon complicates surveillance and may cause hidden dissemination in hospitals.
Studies have identified NDM-1 genes in surface waters, sewage, and even drinking water in parts of South Asia, highlighting environmental reservoirs beyond clinical settings. This increases the risk of community-acquired infections. (CDC)
Diagnosing NDM-1 infections requires specialized laboratory techniques such as polymerase chain reaction (PCR) tests or metallo-β-lactamase phenotypic assays. However, many routine clinical labs lack rapid, standardized tests for NDM-1, delaying detection and infection control measures. (SpringerLink)
Moreover, silent or low-expressing carriers often evade detection with standard susceptibility tests, making screening and surveillance more difficult. (PubMed)
When bacteria carry NDM-1, they often show resistance across multiple antibiotic classes, including:
In many cases, only colistin, tigecycline, or rarely fosfomycin retain activity. However, these drugs have limitations:
Some experimental treatments such as combinations with beta-lactamase inhibitors (e.g., aztreonam-avibactam) or novel inhibitors of metallo-β-lactamases are in development. However, no widely approved inhibitors specifically targeting NDM-1 exist in clinical practice yet. Research continues in academia and industry to find effective countermeasures. (American Chemical Society Publications)
NDM-1 has spread globally since its discovery. Travel, medical tourism, and international healthcare exposure have helped it appear in Europe, North America, and elsewhere. A major 2025 report from the CDC noted a dramatic rise, over 460%, in infections caused by NDM-producing carbapenem-resistant Enterobacterales (CRE) in the United States between 2019 and 2023. These infections are associated with severe outcomes including pneumonia, bloodstream infections, and urinary tract infections.
Reports of NDM-1 positive isolates have emerged in clinical settings across Africa and the Middle East, showing that resistance is not confined to any single region. In southwest Nigeria, for example, a high proportion of Klebsiella pneumoniae isolates tested positive for NDM-1. (PubMed)
Environmental studies also show that NDM-1 genes can be found in wastewater, sewage and surface water, particularly in areas with inadequate sanitation. (CDC)
These measures help reduce the transmission of NDM-1 producing bacteria in hospitals. (SpringerLink)
Overuse and misuse of antibiotics accelerate resistance. Antimicrobial stewardship programs encourage:
These practices reduce selective pressure that drives resistance evolution. (PMC)
Robust surveillance programs that can rapidly detect NDM-1 and other carbapenemases are critical. Early detection enables containment measures to be enacted before widespread transmission occurs. (SpringerLink)
NDM-1 is part of a larger global crisis of antimicrobial resistance (AMR). As bacteria evolve mechanisms to evade every class of antibiotic, the effectiveness of modern medicine is threatened. Routine surgeries, cancer chemotherapy, and management of chronic diseases all depend on reliable antibiotics.
The spread of NDM-1 underscores the interconnectedness of human health, environmental policy, pharmaceutical practices, and global travel. Combating AMR requires a multidisciplinary and international response.
This blog is for informational purposes only and should not be taken as medical advice. It does not replace consultation with a qualified healthcare professional. If you suspect an infection or have health concerns, seek guidance from a licensed clinician. The content is based on publicly available scientific literature and health reports; while efforts have been made to ensure accuracy, research on antimicrobial resistance continues to evolve.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.